68 pending office actions • 9 clients
| Client (Assignee) | Pending OAs |
|---|---|
| Pfizer, Inc. | 33 |
| Pfizer, Inc. | 18 |
| Arena Pharmaceuticals, Inc. | 7 |
| Global Blood Therapeutics, Inc. | 4 |
| Pfizer Inc. | 2 |
| Wyeth LLC | 1 |
| Pfizer Inc. | 1 |
| Hospira, Inc. | 1 |
| Reviral Limited | 1 |
| App # | Title | Client | Examiner | Art Unit | Status | Filed |
|---|---|---|---|---|---|---|
| 18722084 | DIGITAL MEDICINE COMPANION FOR TREATING AND MANAGING SKIN DISEASES | Pfizer, Inc. | MPAMUGO, CHINYERE | 3685 | Non-Final OA | Jun 20, 2024 |
| 18722420 | WEARABLE COMPANION FOR DETECTING THE CYTOKINE RELEASE SYNDROME | Pfizer, Inc. | ABDULLAH, AAISHA | 3681 | Non-Final OA | Jun 20, 2024 |
| 18739401 | POLYNUCLEOTIDE COMPOSITIONS AND USES THEREOF | Pfizer, Inc. | OGUNBIYI, OLUWATOSIN A | 1645 | Non-Final OA | Jun 11, 2024 |
| 18634326 | Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof | Pfizer, Inc. | OGUNBIYI, OLUWATOSIN A | 1645 | Non-Final OA | Apr 12, 2024 |
| 18700075 | CGRP Antagonists for Treating Trigeminal Neuralgia | Pfizer Inc. | INAM, SAHAR | 1622 | Non-Final OA | Apr 10, 2024 |
| 18682162 | MODULATORS OF THE BETA-3 ADRENERGIC RECEPTOR USEFUL FOR THE TREATMENT OR PREVENTION OF HEART FAILURE | Arena Pharmaceuticals, Inc. | SHIAO, REI TSANG | 1691 | Non-Final OA | Feb 08, 2024 |
| 18535116 | IMMUNOGENIC COMPOSITIONS AND METHODS FOR ELICITING AN IMMUNE RESPONSE AGAINST CLOSTRIDIOIDES (CLOSTRIDIUM) DIFFICILE | Pfizer, Inc. | HAUK TEODORO, PRICILA NMN | 1645 | Non-Final OA | Dec 11, 2023 |
| 18533167 | IMMUNOGENIC COMPOSITIONS AND USES THEREOF | Pfizer, Inc. | GILL, RACHEL B | 1671 | Non-Final OA | Dec 07, 2023 |
| 18566862 | Administration of a Compound to Individuals with Hepatic Impairment | Arena Pharmaceuticals, Inc. | TRAN, ERIC | 1629 | Non-Final OA | Dec 04, 2023 |
| 18565626 | METHODS OF TREATMENT | Arena Pharmaceuticals, Inc. | VALENROD, YEVGENY | 1628 | Non-Final OA | Nov 30, 2023 |
| 18513738 | Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof | Pfizer, Inc. | LYONS, MARY M | 1645 | Non-Final OA | Nov 20, 2023 |
| 18557987 | VACCINATION AGAINST BACTERIAL AND BETACORONAVIRUS INFECTIONS | Pfizer, Inc. | FOLEY, SHANON A | 1671 | Non-Final OA | Oct 30, 2023 |
| 18488191 | COMPOUND FOR THE TREATMENT OF CANCER | Pfizer, Inc. | KLINKEL, KORTNEY L | 1627 | Non-Final OA | Oct 17, 2023 |
| 18552453 | Ether-Linked Antiviral Compounds | Pfizer, Inc. | ANDERSON, REBECCA L | 1626 | Non-Final OA | Sep 26, 2023 |
| 18551038 | PHARMACEUTICAL COMPOSITIONS CONTAINING ADENO-ASSOCIATED VIRAL VECTOR | Pfizer, Inc. | SMITH, ADAM MICHAEL | 1638 | Non-Final OA | Sep 18, 2023 |
| 18548622 | Methods of Treatment with Selective CB2 Receptor Agonists | Arena Pharmaceuticals, Inc. | BELL, SARA ELIZABETH | 1625 | Non-Final OA | Sep 01, 2023 |
| 18459381 | CELL CULTURE PROCESS | Pfizer, Inc. | NGUYEN, NGHI V | 1653 | Non-Final OA | Aug 31, 2023 |
| 18547244 | BENZODIAZEPINES FOR TREATING OR PREVENTING RESPIRATORY SYNCYTIAL VIRUS INFECTION | Pfizer, Inc. | JAVANMARD, SAHAR | 1622 | Non-Final OA | Aug 21, 2023 |
| 18446883 | COMPOSITIONS AND METHODS FOR ELICITING AN IMMUNE RESPONSE AGAINST CLOSTRIDIUM DIFFICILE | Pfizer, Inc. | GANGLE, BRIAN J | 1645 | Non-Final OA | Aug 09, 2023 |
| 18275634 | Methods of Protecting RNA | Pfizer, Inc. | MCKILLOP, JOHN CHARLES | 1637 | Non-Final OA | Aug 03, 2023 |
| 18363152 | ANTI- IL27R ANTIBODIES AND METHODS OF USE THEREOF | Pfizer, Inc. | XIAO, YAN | 1642 | Non-Final OA | Aug 01, 2023 |
| 18359250 | Dosing Regime For Treatment of Chronic Hand Eczema | Pfizer, Inc. | BREDEFELD, RACHAEL EVA | 3786 | Non-Final OA | Jul 26, 2023 |
| 18262791 | PHARMACEUTICAL COMPOSITIONS OF CGRP INHIBITORS AND METHODS OF THEIR USE | Pfizer Inc. | IVANOVA, SVETLANA M | 1627 | Non-Final OA | Jul 25, 2023 |
| 18350986 | CELLS AND METHOD OF CELL CULTURE | Pfizer, Inc. | HUMPHRIES, NICHOLAS ADAM | 1631 | Non-Final OA | Jul 12, 2023 |
| 18347698 | SELF-AMPLIFYING RNA ENCODING AN INFLUENZA VIRUS ANTIGEN | Pfizer, Inc. | CHEN, STACY BROWN | 1672 | Non-Final OA | Jul 06, 2023 |
| 18268959 | SOLID FORMS OF A CDK2 INHIBITOR | Pfizer, Inc. | MCDOWELL, BRIAN E | 1624 | Non-Final OA | Jun 21, 2023 |
| 18335259 | IL-12 Variants and Uses Thereof | Pfizer, Inc. | GODDARD, LAURA B | 1642 | Non-Final OA | Jun 15, 2023 |
| 18255869 | METHODS AND COMPOSITIONS FOR INHIBITING EXCESS NUCLEIC ACID PRECIPITATION | Pfizer, Inc. | TSAY, MARSHA M | 1656 | Non-Final OA | Jun 04, 2023 |
| 18255868 | METHODS FOR PURIFICATION OF AAV VECTORS BY AFFINITY CHROMATOGRAPHY | Pfizer, Inc. | TINSLEY, BRENDAN THOMAS | 1634 | Non-Final OA | Jun 04, 2023 |
| 18255870 | METHODS AND COMPOSITIONS FOR INHIBITING EXCESS NUCLEIC ACID PRECIPITATION | Pfizer, Inc. | MCCORMICK, CATHERINE LYNN | 1638 | Non-Final OA | Jun 04, 2023 |
| 18319943 | Antibodies Specific for CD47, PD-L1, and Uses Thereof | Pfizer, Inc. | MOSELEY II, NELSON B | 1642 | Non-Final OA | May 18, 2023 |
| 18036141 | TALAZOPARIB SOFT GELATIN CAPSULE DOSAGE FORM | Pfizer, Inc. | MERCIER, MELISSA S | 1615 | Final Rejection | May 09, 2023 |
| 18252124 | Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof | Pfizer, Inc. | OGUNBIYI, OLUWATOSIN A | 1645 | Non-Final OA | May 08, 2023 |
| 18034239 | IMMUNOGENIC COMPOSITIONS FOR USE IN PNEUMOCOCCAL VACCINES | Pfizer, Inc. | MORGAN, BAILEY MICHELLE | 1645 | Non-Final OA | Apr 27, 2023 |
| 18250570 | CRYSTAL-FREE HIGH-CONCENTRATION TESTOSTERONE CYPIONATE FORMULATIONS | Pfizer, Inc. | MITCHELL, EDWIN COLEMAN | 1619 | Final Rejection | Apr 26, 2023 |
| 18250596 | METHODS OF TREATING CONDITIONS RELATED TO THE S1P1 RECEPTOR | Arena Pharmaceuticals, Inc. | JEAN-LOUIS, SAMIRA JM | 1642 | Non-Final OA | Apr 26, 2023 |
| 18250252 | Methods for Purification of AAV Vectors by Anion Exchange Chromatography | Pfizer, Inc. | ALAM, DANYAL HASSAN | 1672 | Non-Final OA | Apr 24, 2023 |
| 18249774 | ISOXAZOLE DERIVATIVES AS MODULATORS OF THE 5-HT2A SEROTONIN RECEPTOR USEFUL FOR THE TREATMENT OF DISORDERED RELATED THERETO | Arena Pharmaceuticals, Inc. | BRAUN, MADELINE E | 1624 | Non-Final OA | Apr 20, 2023 |
| 18249411 | Methods for purifying bacterial polysaccharides | Pfizer, Inc. | PATEL, PRANAV N | 1777 | Non-Final OA | Apr 18, 2023 |
| 18301475 | Benzimidazole Derivative Compounds and Uses Thereof | Pfizer, Inc. | HASTINGS, ALISON AZAR | 1627 | Non-Final OA | Apr 17, 2023 |
| 18247565 | Cell culture process for producing RSV F protein | Pfizer, Inc. | CHESTNUT, BARRY A | 1672 | Non-Final OA | Mar 31, 2023 |
| 18025879 | METHODS, THERAPIES AND USES FOR TREATING CANCER | Pfizer, Inc. | HOLTZMAN, KATHERINE ANN | 1646 | Non-Final OA | Mar 10, 2023 |
| 18043271 | COMPUTERIZED DECISION SUPPORT TOOL AND MEDICAL DEVICE FOR RESPIRATORY CONDITION MONITORING AND CARE | Pfizer, Inc. | HOFFPAUIR, ANDREW ELI | 3791 | Non-Final OA | Feb 27, 2023 |
| 18042054 | Stable Topical Formulations of 1(R)-4-(5-(4-Methoxy-3-Propoxphenyl)Pyridin-3-YL)-1,2-OX-Aborolan-2-OL | Pfizer, Inc. | THOMAS, TIMOTHY P | 1614 | Non-Final OA | Feb 17, 2023 |
| 18041447 | Methods of Protecting RNA | Pfizer, Inc. | BATES, KEENAN ALEXANDER | 1631 | Non-Final OA | Feb 13, 2023 |
| 18019379 | UREA DERIVATIVES AS PYRUVATE KINASE ACTIVATORS | Global Blood Therapeutics, Inc. | RODRIGUEZ, RAYNA B | 1628 | Non-Final OA | Feb 02, 2023 |
| 18006800 | IMPROVEMENTS TO WASH SOLUTIONS FOR ANION EXCHANGE CHROMATOGRAPHY IN A METHOD OF PURIFICATION OF RECOMBINANTLY-PRODUCED RSV PROTEINS | Pfizer, Inc. | IANNUZO, NATALIE NMN | 1653 | Non-Final OA | Jan 25, 2023 |
| 18004965 | Polymorphs of (1S,2S,3S,5R)-3-((6-(Difluoromethyl)-5-Fluoro-1,2,3,4-Tetrahydroisoquinolin-8-YL)OXY)-5-(4-Methyl-7H-Pyrrolo[2,3-D]Pyrimidin-7-YL)Cyclopentane-1,2-DIOL Mono-Hydrochloride | Pfizer, Inc. | HIRAKIS, SOPHIA P | 1623 | Non-Final OA | Jan 10, 2023 |
| 18066591 | COMPOSITIONS RELATING TO A MUTANT CLOSTRIDIUM DIFFICILE TOXIN AND METHODS THEREOF | Wyeth LLC | SHAHNAN SHAH, KHATOL S | 1645 | Non-Final OA | Dec 15, 2022 |
| 17991448 | MODULATORS OF HEMOGLOBIN | Global Blood Therapeutics, Inc. | JARRELL, NOBLE E | 1699 | Final Rejection | Nov 21, 2022 |
| 17990068 | COMPOUNDS AND METHODS FOR TREATMENT OF PRIMARY BILIARY CHOLANGITIS | Arena Pharmaceuticals, Inc. | PIHONAK, SARAH | 1627 | Non-Final OA | Nov 18, 2022 |
| 17924975 | METHODS, THERAPIES AND USES FOR TREATING CANCER | Pfizer, Inc. | DENT, ALANA HARRIS | 1643 | Final Rejection | Nov 11, 2022 |
| 17997273 | METHODS OF USE FOR PYRIMIDINES AS FERROPORTIN INHIBITORS | Global Blood Therapeutics, Inc. | LEE, CHIHYI NMN | 1628 | Final Rejection | Oct 27, 2022 |
| 17997091 | PYRROLO[2,3-D]PYRIMIDINE DERIVATIVES | Pfizer, Inc. | WILLIS, DOUGLAS M | 1624 | Non-Final OA | Oct 25, 2022 |
| 18045967 | RNA MOLECULES | Pfizer, Inc. | CHEN, STACY BROWN | 1672 | Non-Final OA | Oct 12, 2022 |
| 17758095 | Stable Immediate Release Tablet and Capsule Formulations of 1-((2S,5R)-5-((7H-Pyrrolo[2,3-D]Pyrimidin-4-YL)Amino)-2-Methylpiperidin-1-YL)Prop-2-EN-1-One | Pfizer Inc. | HELM, CARALYNNE E | 1615 | Final Rejection | Jun 28, 2022 |
| 17787454 | SURFACE MODIFYING COATING FOR MEDICAL DEVICES | Hospira, Inc. | VASISTH, VISHAL V | 1771 | Non-Final OA | Jun 20, 2022 |
| 17777909 | METHODS OF ADMINISTERING VOXELOTOR | Global Blood Therapeutics, Inc. | SANCHEZ, JUSTIN CHRISTOPHER | 1622 | Final Rejection | May 18, 2022 |
| 17733566 | IMMUNOGENIC COMPOSITION AGAINST INFLUENZA | Pfizer, Inc. | LI, BAO Q | 1671 | Final Rejection | Apr 29, 2022 |
| 17770455 | BENZODIAZEPINE DERIVATIVES FOR TREATING A RESPIRATORY SYNCYTIAL VIRUS (RSV) INFECTION | Reviral Limited | BURKETT, DANIEL JOHN | 1624 | Final Rejection | Apr 20, 2022 |
| 17607341 | REAL-TIME TRACKING AND MANAGEMENT OF STANDARD WORKFLOWS | Pfizer, Inc. | KONERU, SUJAY | 3624 | Final Rejection | Oct 28, 2021 |
| 17431462 | Methods for purifying bacterial polysaccharides | Pfizer, Inc. | CREWS, JARET JAMES | 1691 | Non-Final OA | Aug 17, 2021 |
| 17312185 | Immunogenic Multiple Hetero-Antigen Polysaccharide-Protein Conjugates and uses thereof | Pfizer, Inc. | FOLEY, SHANON A | 1671 | Non-Final OA | Jun 09, 2021 |
| 17299180 | Cells with reduced inhibitor production and methods of use thereof | Pfizer, Inc. | SPANGLER, JOSEPH RANKIN | 1656 | Final Rejection | Jun 02, 2021 |
| 17283801 | Dosage Regimen for TFPI Antagonists | Pfizer, Inc. | ALSOMAIRY, SARAH ABDOALATIF | 1646 | Final Rejection | Apr 08, 2021 |
| 17125555 | STREPTOCOCCUS PNEUMONIAE CAPSULAR POLYSACCHARIDES AND CONJUGATES THEREOF | Pfizer, Inc. | LYONS, MARY M | 1645 | Final Rejection | Dec 17, 2020 |
| 16978354 | ANTI-PD-1 ANTIBODY COMPOSITIONS | Pfizer, Inc. | ALSOMAIRY, SARAH ABDOALATIF | 1646 | Final Rejection | Sep 04, 2020 |
| 15761777 | Method Of Preparing A Therapeutic Protein Formulation And Antibody Formulation Produced By Such A Method | Pfizer, Inc. | KIM, YUNSOO | 1641 | Final Rejection | Mar 20, 2018 |
IP Author helps law firms respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial